This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schipper, M. L. Articles by Behr, T. M. Search for Related Content PubMed PubMed Citation Articles by Schipper, M. L. Articles by Behr, T. M.

Radioiodide Treatment after Sodium Iodide Symporter Gene Transfer Is a Highly Effective Therapy in Neuroendocrine Tumor Cells¹

Departments of Nuclear Medicine [M. L. S., A. W., M. B., T. M. B.], Gastroenterology, Endocrinology, and Metabolism [R. G., W. J., H. S., T. B., B. S., R. A., A. E. H.], and Clinical Research Unit for Gastrointestinal Endocrinology [R. G., H. S.], Philipps University Marburg, 35043 Marburg, Germany

This study evaluates the possibility of treating Bon1 and QGP pancreatic neuroendocrine tumor cells with radioactive iodide (¹³¹I) after stable transfection with the thyroid sodium iodide symporter (NIS). NIS expression was driven either by the strong viral cytomegalovirus promoter or by the tissue-specific chromogranin A promoter. Using either approach, NIS expression was confirmed by reverse transcription-PCR and Western blotting. Uptake of radioactive iodide was increased 20-fold by chromogranin A promoter-driven NIS expression and 50-fold by cytomegalovirus promoter-driven NIS expression. Maximal uptake was reached within 15 min in QGP cells and 30 min in Bon1 cells. Effective half-life was 5 min in QGP and 30 min in Bon1 cells. No evidence of organification was detected by high-performance liquid chromatography and gel filtration chromatography. ¹³¹I was a highly effective treatment in NIS-expressing QGP and Bon1 cells, reducing clone formation by 99.83 and 98.75%, respectively, in the in vitro clonogenic assay. In contrast, clone formation was not reduced in QGP and Bon1 cells without NIS expression after incubation with the same activity concentration of ¹³¹I as compared with mock treated cells. Absorbed doses to QGP and Bon1 cells are up to 150 and 30 Gy, respectively. In addition, a direct cytotoxic effect of radioiodide was demonstrated in NIS-expressing Bon1 cells after ¹³¹I incubation. In conclusion, radioiodide treatment after NIS gene transfer appears to be a promising novel approach in the therapy of neuroendocrine tumors if its highly encouraging in vitro effectiveness can be transferred to the in vivo situation.

This article has been cited by other articles:

				K. I. Kim, J. H. Kang, J.-K. Chung, Y. J. Lee, J. M. Jeong, D. S. Lee, and M. C. Lee Doxorubicin Enhances the Expression of Transgene Under Control of the CMV Promoter in Anaplastic Thyroid Carcinoma Cells J. Nucl. Med., September 1, 2007; 48(9): 1553 - 1561. [Abstract] [Full Text] [PDF]

				J. Leja, H. Dzojic, E. Gustafson, K. Oberg, V. Giandomenico, and M. Essand A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2455 - 2462. [Abstract] [Full Text] [PDF]

				L. Chen, A. Altmann, W. Mier, H. Eskerski, K. Leotta, L. Guo, R. Zhu, and U. Haberkorn Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene J. Nucl. Med., May 1, 2006; 47(5): 854 - 862. [Abstract] [Full Text] [PDF]

				T. Petrich, L. Quintanilla-Martinez, Z. Korkmaz, E. Samson, H. J. Helmeke, G. J. Meyer, W. H. Knapp, and E. Potter Effective Cancer Therapy with the {alpha}-Particle Emitter [211At]Astatine in a Mouse Model of Genetically Modified Sodium/Iodide Symporter-Expressing Tumors Clin. Cancer Res., February 15, 2006; 12(4): 1342 - 1348. [Abstract] [Full Text] [PDF]

				N. Cengic, C. H. Baker, M. Schutz, B. Goke, J. C. Morris, and C. Spitzweg A Novel Therapeutic Strategy for Medullary Thyroid Cancer Based on Radioiodine Therapy following Tissue-Specific Sodium Iodide Symporter Gene Expression J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4457 - 4464. [Abstract] [Full Text] [PDF]

				J. Faivre, J. Clerc, R. Gerolami, J. Herve, M. Longuet, B. Liu, J. Roux, F. Moal, M. Perricaudet, and C. Brechot Long-Term Radioiodine Retention and Regression of Liver Cancer after Sodium Iodide Symporter Gene Transfer in Wistar Rats Cancer Res., November 1, 2004; 64(21): 8045 - 8051. [Abstract] [Full Text] [PDF]

				J. H. Kang, J.-K. Chung, Y. J. Lee, J. H. Shin, J. M. Jeong, D. S. Lee, and M. C. Lee Establishment of a Human Hepatocellular Carcinoma Cell Line Highly Expressing Sodium Iodide Symporter for Radionuclide Gene Therapy J. Nucl. Med., September 1, 2004; 45(9): 1571 - 1576. [Abstract] [Full Text] [PDF]

				I. L. Wapnir, M. Goris, A. Yudd, O. Dohan, D. Adelman, K. Nowels, and N. Carrasco The Na+/I- Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the Thyroid Clin. Cancer Res., July 1, 2004; 10(13): 4294 - 4302. [Abstract] [Full Text] [PDF]

				U. Haberkorn, P. Beuter, W. Kubler, H. Eskerski, M. Eisenhut, R. Kinscherf, S. Zitzmann, L. G. Strauss, A. Dimitrakopoulou-Strauss, and A. Altmann Iodide Kinetics and Dosimetry In Vivo After Transfer of the Human Sodium Iodide Symporter Gene in Rat Thyroid Carcinoma Cells J. Nucl. Med., May 1, 2004; 45(5): 827 - 833. [Abstract] [Full Text] [PDF]